NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...
"The development of the Teoxane RHA ® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," states Valérie Taupin, Founder and CEO of Teoxane. "Mepivacaine represents the first ...
There is a new type of hyaluronic acid (HA) facial filler on the market called RHA®, a collaboration between the U.S. company Revance and the Swiss manufacturer Teoxane. MARICE COHN BAND MIAMI HERALD ...
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational ...
Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results